Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.47 |
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | PPARD | Q03181 | 7/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12214578 | 0.87 | HSD17B1 (0.45) | FFAR1PPARGPPARDHSD17B1MIF | |
| SCHEMBL435248 | 0.86 | FFAR1 (0.53) | FFAR1PPARGPPARDMIFPPARA | |
| SCHEMBL9275740 | 0.86 | FFAR1 (0.53) | FFAR1PPARGPPARDMIFPPARA | |
| SCHEMBL9277990 | 0.86 | FFAR1 (0.53) | FFAR1PPARGPPARDMIFPPARA | |
| SCHEMBL31674096 | 0.86 | L3MBTL1 (0.48) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL16188897 | 0.84 | CYP3A4 (0.52) | FFAR1PPARGPPARD | |
| SCHEMBL15791414 | 0.84 | PPARG (0.46) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL16188863 | 0.84 | FFAR1 (0.45) | FFAR1PPARGPPARD | |
| SCHEMBL3349544 | 0.82 | L3MBTL1 (0.49) | FFAR1PPARGPPARDPPARA | |
| SCHEMBL13264506 | 0.82 | FFAR1 (0.65) | FFAR1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022194-B1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-9573957-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-21 | — | — | US | disclosed |
| US-9573957-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-21 | — | — | US | disclosed |
| EP-2885285-B1 | PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-10-19 | — | — | EP | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| CN-104870429-A | Benzofuran derivative, preparation method therefor, and medical application thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2015-08-26 | — | — | CN | disclosed |
| WO-2015009611-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7759493-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759493-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | MERCK & CO., INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | MERCK & CO., INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2008054675-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054674-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, FFAR2, GPR65 | FFAR1 8/4885PPARG 7/4885PPARD 19/4885 |
| US-20090312303-A1 | Antidiabetic Bicyclic Compounds | GPR119, GPR55, GPR65 | FFAR1 12/4885PPARG 7/4885PPARD 15/4885 |
| US-20140031339-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | LTA4H, LTB4R, LTB4R2 | FFAR1 321/4885PPARG 2059/4885PPARD 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.